



RECEIVED #11

AUG 26 2003

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Takashi HAYAMA et al.

Serial No. 10/031,795

Filed April 2, 2002

BIARYLUREA DERIVATIVES

Confirmation No. 1703

Docket No. 2002\_0054A

Group Art Unit 1188

Examiner Kahsay Habte

RECEIVED  
JUL 30 2003  
TC 1700

RECEIVED  
JUL 31 2003  
TECH CENTER 1600/2900

RESPONSE

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This is responsive to the Official Action dated May 30, 2003, the time for responding thereto being extended for one month in accordance with a petition for extension submitted concurrently herewith.

The Official Action constitutes a requirement for restriction.

Applicants elect to prosecute the invention of Group II, with traverse.

It is respectfully requested that the restriction requirement be reconsidered. It is respectfully submitted that the inventions of Groups I-IX do relate to a single general concept.

The present claims satisfy the unity of the invention because all claims are common in that all of the compounds have the spiro chemical structure and the same utility, i.e. the same pharmaceutical effect.

Particularly, Group II, Group IV and spirooxazole of Group IX are the same in having 1,3-oxazole. Therefore, at least, Group II, Group IV and spirooxazole of Group IX should be recognized to satisfy the unity of the invention.

Favorable reconsideration and action on the merits is solicited.

Respectfully submitted,

Takashi HAYAMA et al.

By: Warren Cheek  
Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/dlk  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
July 29, 2003